- The combination of intratumoral sotigalimab and systemic pembrolizumab was well-tolerated and demonstrated an improved clinical response rate relative to the standard of care, pembrolizumab monotherapy-
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/be19ab99-a0c8-4850-a0a4-1592fdc18600
WESTLAKE VILLAGE, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in an upcoming investor conference.
REDWOOD CITY, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”)(Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced that Biomea’s management will participate in a fireside chat and host investor meetings at the upcoming Piper Sandler 34th Annual Healthcare Conference.
Read this article:
Biomea Fusion to Participate in Piper Sandler 34th Annual Healthcare Conference
THE WOODLANDS, Texas, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 13th Annual Jefferies London Healthcare Conference, taking place November 15-17, 2022.
See the original post:
Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference
Robust two-year X-ray results of medial joint space width (mJSW) and significant pain response in patients with earlier disease highlight the potential of lorecivivint to be a first-in-class, structure-modifying drug for the treatment of knee osteoarthritis Robust two-year X-ray results of medial joint space width (mJSW) and significant pain response in patients with earlier disease highlight the potential of lorecivivint to be a first-in-class, structure-modifying drug for the treatment of knee osteoarthritis
Excerpt from:
Biosplice Announces Data from Recent Clinical Trials in Knee Osteoarthritis and the Initiation of a New Phase 3 Trial
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
See the original post here:
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
Low-dose ICT01 plus low-dose IL-2 safely and significantly increase the number of activated ?9?2 T cells, CD8 T cells, and Natural Killer cells in patients with solid tumors
Here is the original post:
ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting
Three Lakes Foundation brings together academia, clinicians and industry to identify imaging insights for early detection of interstitial lung disease/pulmonary fibrosis (ILD/PF) Three Lakes Foundation brings together academia, clinicians and industry to identify imaging insights for early detection of interstitial lung disease/pulmonary fibrosis (ILD/PF)
More:
Paving the way for better diagnosis, treatment and care in pulmonary fibrosis
COPENHAGEN, Denmark – November 11, 2022 - Bavarian Nordic A/S (OMX: BAVA) today announced that Paul Chaplin, President & CEO will provide a corporate presentation at the Jefferies 2022 London Healthcare Conference on Thursday, November 17, 2022 at 8:35 am GMT (9:35 am CET).
Continue reading here:
Bavarian Nordic to Present at Jefferies 2022 London Healthcare Conference